Silverfin false false 31/12/2024 01/01/2024 31/12/2024 Dr D B Agus 12/04/2024 Professor Sir J I Bell 13/12/2024 T J Berry D Crook L M Flashner 13/05/2024 Dr S J Hoosdally 05/10/2024 Professor A T Makadzange 12/04/2024 Professor G McVean 13/12/2024 J V Mistry 05/10/2024 17 June 2025 The principal activity of the company continued to be that of providing equitable access to rapid genomic sequencing analysis, to help better manage the spread of infectious diseases. 13776371 2024-12-31 13776371 bus:Director1 2024-12-31 13776371 bus:Director2 2024-12-31 13776371 bus:Director5 2024-12-31 13776371 bus:Director6 2024-12-31 13776371 bus:Director7 2024-12-31 13776371 bus:Director8 2024-12-31 13776371 bus:Director9 2024-12-31 13776371 2023-12-31 13776371 core:CurrentFinancialInstruments 2024-12-31 13776371 core:CurrentFinancialInstruments 2023-12-31 13776371 core:RetainedEarningsAccumulatedLosses 2024-12-31 13776371 core:RetainedEarningsAccumulatedLosses 2023-12-31 13776371 core:PatentsTrademarksLicencesConcessionsSimilar 2023-12-31 13776371 core:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 13776371 core:ComputerEquipment 2023-12-31 13776371 core:ComputerEquipment 2024-12-31 13776371 2024-01-01 2024-12-31 13776371 bus:FilletedAccounts 2024-01-01 2024-12-31 13776371 bus:SmallEntities 2024-01-01 2024-12-31 13776371 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13776371 bus:CompanyLimitedByGuarantee 2024-01-01 2024-12-31 13776371 bus:Director1 2024-01-01 2024-12-31 13776371 bus:Director2 2024-01-01 2024-12-31 13776371 bus:Director3 2024-01-01 2024-12-31 13776371 bus:Director4 2024-01-01 2024-12-31 13776371 bus:Director5 2024-01-01 2024-12-31 13776371 bus:Director6 2024-01-01 2024-12-31 13776371 bus:Director7 2024-01-01 2024-12-31 13776371 bus:Director8 2024-01-01 2024-12-31 13776371 bus:Director9 2024-01-01 2024-12-31 13776371 core:PatentsTrademarksLicencesConcessionsSimilar core:TopRangeValue 2024-01-01 2024-12-31 13776371 core:PatentsTrademarksLicencesConcessionsSimilar 2024-01-01 2024-12-31 13776371 core:ComputerEquipment core:TopRangeValue 2024-01-01 2024-12-31 13776371 2023-01-01 2023-12-31 13776371 core:ComputerEquipment 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Company No: 13776371 (England and Wales)

THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

(A company limited by guarantee)

Unaudited Financial Statements
For the financial year ended 31 December 2024
Pages for filing with the registrar

THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2024

Contents

THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

BALANCE SHEET

As at 31 December 2024
THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

BALANCE SHEET (continued)

As at 31 December 2024
Note 2024 2023
£ £
Fixed assets
Intangible assets 3 66,660 0
Tangible assets 4 0 9,755
66,660 9,755
Current assets
Debtors 5 212,139 97,620
Cash at bank and in hand 624,663 1,177,867
836,802 1,275,487
Creditors: amounts falling due within one year 6 ( 659,831) ( 1,074,651)
Net current assets 176,971 200,836
Total assets less current liabilities 243,631 210,591
Provision for liabilities 0 ( 2,439)
Net assets 243,631 208,152
Reserves
Profit and loss account 243,631 208,152
Total reserves 243,631 208,152

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of The Global Pathogen Analysis Service Limited (registered number: 13776371) were approved and authorised for issue by the Board of Directors on 17 June 2025. They were signed on its behalf by:

L M Flashner
Director
THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

The Global Pathogen Analysis Service Limited (the Company) is a private company limited by guarantee, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 128 City Road, London, EC1V 2NX, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with ‘The Financial Reporting Standard applicable in the UK and the Republic of Ireland’ issued by the Financial Reporting Council, including Section 1A of Financial Reporting Standard 102 (FRS102), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The functional currency of The Global Pathogen Analysis Service Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates.

Turnover

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Recharged expenses
Revenue from recharged expenses is recognised when the service has been provided.

Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Statement of Income and Retained Earnings in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on enacted or substantively enacted tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Trademarks, patents and licences 3 years straight line
Trademarks, patents and licences

Separately acquired licences are included at cost and amortised in equal annual instalments over a period of 3 years, which is their estimated useful economic life. Provision is made for any impairment.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Computer equipment 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 6 6

3. Intangible assets

Trademarks, patents
and licences
Total
£ £
Cost
At 01 January 2024 0 0
Additions 75,000 75,000
At 31 December 2024 75,000 75,000
Accumulated amortisation
At 01 January 2024 0 0
Charge for the financial year 8,340 8,340
At 31 December 2024 8,340 8,340
Net book value
At 31 December 2024 66,660 66,660
At 31 December 2023 0 0

4. Tangible assets

Computer equipment Total
£ £
Cost
At 01 January 2024 16,879 16,879
Disposals ( 16,879) ( 16,879)
At 31 December 2024 0 0
Accumulated depreciation
At 01 January 2024 7,124 7,124
Charge for the financial year 1,758 1,758
Disposals ( 8,882) ( 8,882)
At 31 December 2024 0 0
Net book value
At 31 December 2024 0 0
At 31 December 2023 9,755 9,755

5. Debtors

2024 2023
£ £
Trade debtors 208,100 0
Corporation tax 0 81,299
Other debtors 4,039 16,321
212,139 97,620

6. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 0 18,647
Taxation and social security 125,353 19,374
Other creditors 534,478 1,036,630
659,831 1,074,651

7. Liability of members

The members of the The Global Pathogen Analysis Service Limited have undertaken to contribute a sum not exceeding £1 each to meet the liabilities of the Company if it should be wound up.